Yeon-Ah Lee

A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study

Won Park, Paweł Hrycaj, Volodymyr Kovalenko et al. · Annals of the Rheumatic Diseases · 2013 · 601 citations · Full text

Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial

Désirée van der Heijde, James Cheng‐Chung Wei, Maxime Dougados et al. · The Lancet · 2018 · 349 citations · Full text

Inflammation, Rheumatology, Rheumatoid Disorder +14

Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study

Won Park, Dae‐Hyun Yoo, Pedro C. Miranda et al. · Annals of the Rheumatic Diseases · 2016 · 227 citations · Full text

Adiponectin may contribute to synovitis and joint destruction in rheumatoid arthritis by stimulating vascular endothelial growth factor, matrix metalloproteinase-1, and matrix metalloproteinase-13 expression in fibroblast-like synoviocytes more than proinflammatory mediators

Hyunmi Choi, Yeon-Ah Lee, Sanghoon Lee et al. · Arthritis Research & Therapy · 2009 · 110 citations · Full text

Expression levels and association of gelatinases MMP-2 and MMP-9 and collagenases MMP-1 and MMP-13 with VEGF in synovial fluid of patients with arthritis

Kyoung Soo Kim, Hyun Mi Choi, Yeon-Ah Lee et al. · Rheumatology International · 2010 · 107 citations

Inflammation, Rheumatology, Expression Levels +15